<DOC>
	<DOCNO>NCT01499251</DOCNO>
	<brief_summary>This open-label , single arm , Phase 1 study ass safety tolerability macitentan combination dose-dense temozolomide adult patient recurrent glioblastoma gliosarcoma . The study compose three part . A Phase 1 Dose Escalation Period traditional 3+3 design determine maximum tolerate dose macitentan combination dose-dense temozolomide . A Phase 1b Period expand safety tolerability data two dos macitentan dose-dense temozolomide select Dose Escalation Period explore efficacy . An Ancillary Study evaluate effect macitentan biomarkers brain tumor tissue . The study plan minimum duration 12 month . The study end patient ( exclude prematurely withdraw lose follow-up ) part study complete visit month 12 30 day safety follow-up .</brief_summary>
	<brief_title>Clinical Study Safety Tolerability Macitentan Combination With Dose-dense Temozolomide Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm glioblastoma multiforme gliosarcoma Recurrent disease : interval least 3 month follow initial radiotherapy temozolomide interval least 3 week end surgery recurrent disease start protocol therapy patient undergone surgery recurrent disease KPS 60 % high Adequate bone marrow function Women childbearing potential must negative serum betaHCG pregnancy test document within 14 day prior study initiation . Women childbearing potential must agree use two reliable method contraception screen 30 day discontinuation study treatment . Males naturally surgically sterile , female partner childbearing potential , must agree use two reliable method contraception screen 30 day discontinuation study treatment . Exclusion Criteria Histology astrocytoma grade IV ( GBM gliosarcoma ) Tumor focus tentorium beyond cranial vault Glioblastoma gliosarcoma disease leptomeningeal spread Patients history cancer , unless complete remission , therapy disease minimum 5 year Elevated serum aspartate aminotransferase , alanine aminotransferase , bilirubin ( unless medical justification bilirubin elevation , aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase normal ) Moderate severe hepatic impairment Confirmed systolic blood pressure &lt; 100 mmHg diastolic blood pressure &lt; 50 mmHg History orthostatic hypotension Renal insufficiency serum creatinine normal reference range Prior chemotherapy recurrent glioblastoma nitrosourea compound bevacizumab Prior focal radiotherapy Severe , active comorbidity ( e.g . cardiac disease ; respiratory disease ; chronic hepatitis ; hematological bone marrow diseases ; severe malabsorption ) No active cancer No concurrent cytochrome P450 3A4 inducer No concurrent strong cytochrome P450 3A4 inhibitor No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>glioblastoma</keyword>
</DOC>